repository
BROWSE
Cited 0 times in 
Various insight on biological research: analysis through bio-data of cells treated with 2′-fucosyllactose, exogenous nitric oxide on the possibility of wound repair, and ovarian protection on chemotherapy
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.advisor | 김, 미란 | - |
| dc.contributor.author | 장, 동민 | - |
| dc.date.accessioned | 2023-11-16T05:43:56Z | - |
| dc.date.available | 2023-11-16T05:43:56Z | - |
| dc.date.issued | 2023 | - |
| dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/26842 | - |
| dc.language.iso | en | - |
| dc.title | Various insight on biological research: analysis through bio-data of cells treated with 2′-fucosyllactose, exogenous nitric oxide on the possibility of wound repair, and ovarian protection on chemotherapy | - |
| dc.type | Thesis | - |
| dc.identifier.url | http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000032978 | - |
| dc.subject.keyword | Bio data | - |
| dc.subject.keyword | Nitric oxide | - |
| dc.subject.keyword | GV1001 | - |
| dc.description.degree | Doctor | - |
| dc.contributor.department | 대학원 의생명과학과 | - |
| dc.contributor.affiliatedAuthor | 장, 동민 | - |
| dc.date.awarded | 2023 | - |
| dc.type.local | Theses | - |
| dc.citation.date | 2023 | - |
| dc.embargo.liftdate | 9999-12-31 | - |
| dc.embargo.terms | 9999-12-31 | - |
| dc.description.tableOfContents | CHAPTER 1. Network analysis of RNA sequencing in human melanoma cells (MNT-1) through treating with 2'-fucosyllactose 1
1.1. INTRODUCTION 2 1.2. MATERIALS AND METHODS 3 1.2.1 Cell culture and materials 3 1.2.2 RNA sequencing data 3 1.2.3 Identification of differentially expressed genes (DEGs) 4 1.2.4 Functional enrichment analysis and molecular network model 4 1.3. RESULTS 6 1.3.1 Data for analysis is produced from workflow of RNA sequencing data on human melanoma cells (MNT-1) 6 1.3.2 2'-FL occurs change of cellular genes at a systematic analysis 6 1.3.3 Transcriptome analysis proposes 2'-FL-related signaling model 7 1.4. DISCUSSION 8 1.5. FIGURES LEGENDS 10 1.6. REFERENCES 16 CHAPTER 2. Exogenous nitric oxide generated through plasma system promotes collagen expression in human skin fibroblasts by increasing TGF-beta1 via ERK/SMAD pathway 25 2.1. INTRODUCTION 26 2.2. MATERIALS AND METHODS 28 2.2.1 Cell culture and cell viability assay 28 2.2.2 Nitric oxide (NO) generation and quantification 28 2.2.3 Reverse transcription polymerase chain reaction (RT-PCR) 29 2.2.4 Immunoblot assay 29 2.2.5 Immunofluorescence 30 2.2.6 ELISA assay 31 2.2.7 Collagen assay 32 2.2.8 Statistical analysis 32 2.3. RESULTS 33 2.3.1 Microwave plasma system and concentration of nitric oxide (NO) for experiment 33 2.3.2 Viability of cell on nitric oxide (NO) generated various O2 flow rates 33 2.3.3 Levels of collagen 1 type and TGF-beta1 gene increase in human fibroblast cells (adult and neonatal) treated with nitric oxide (NO) 34 2.3.4 Nitric oxide (NO) regulates phosphorylation and translocation of SMAD3 through ERK signaling 35 2.3.5 Nitric oxide (NO) leads to the promotion of collagen by induction of TGF-beta1 through ERK-SMAD3 axis 36 2.4. DISCUSSION 37 2.5. FIGURES LEGENDS 39 2.6. REFERENCES 54 CHAPTER 3. GV1001 protects ovarian function from over-activation of folliculogenesis triggered by an anti-VEGFa agent through VEGFa/AMPK/Foxo3a pathway 59 3.1. INTRODUCTION 60 3.2. MATERIALS AND METHODS 63 3.2.1 Animal 63 3.2.2 Ovarian histology and follicle counting 64 3.2.3 Immunoblot assay 65 3.2.4 Immunohistochemistry assay 66 3.2.5 Immunofluorescence 67 3.2.6 ELISA assay 67 3.2.7 Statistical analysis 68 3.3. RESULTS 69 3.3.1 GV1001 reduces loss of follicle by accelerating follicles activation and growth through anti-VEGFa agent (Bevacizumab) 69 3.3.2 GV1001 deters follicle loss induced by anti-VEGFa agent (Bevacizumab) 71 3.3.3 Co-administration of GV1001 and anti-VEGFa agent (Bevacizumab) maintain the level of AMH to be important as indicator of follicle reserve 71 3.3.4 GV1001 leads to translocation of Foxo3a (forkhead transcription factor) limited by anti-VEGFa agent (Bevacizumab) 72 3.4. DISCUSSION 74 3.5. FIGURES LEGENDS 77 3.6. REFERENCES 91 ABSTRACT (Korean) 95 | - |
- Appears in Collections:
- Theses > Graduate School of Biomedical Sciences > Doctor
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
-
- License
